Pharmacological prevention and treatment in clinical at-risk states for psychosis
Publisher DOI
PubMed ID
22239587
Abstract
Over the last couple of decades, the treatment of psychoses has much advanced; yet, despite all progress, the individual and societal burden associated with psychosis and particularly schizophrenia has largely remained unchanged. Therefore, much hope is currently placed on indicated prevention as a mean to fight these burdens before they set in. Though the number of studies investigating pharmacological interventions is still limited, encouraging results have been reported from the pioneering trials, despite several methodological limitations. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention, but also treatment. In consequence, outcome criteria have to be broadened to cover the current needs of the patients. As is indicated by a recent study successfully using Omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. Treatment studies may become promoted by the proposed introduction of a new disorder category into DSM-V. Future prevention studies, however, need to solve the challenge of changing immediate transition rates, demanding for new risk enrichment strategies as a prerequisite for feasible trial designs.
Date Issued
2012
Publication Type
Article
Language(s)
en
Author(s)
Ruhrmann, Stephan | |
Klosterkötter, Joachim | |
Bodatsch, Mitja | |
Bechdolf, Andreas | |
Nikolaides, Alexandra | |
Hilboll, Desiree |
Additional Credits
Journal
Current pharmaceutical design
Publisher
Bentham Science Publishers
ISSN
1381-6128
Access(Rights)
metadata.only